Skip to main content
Premium Trial:

Request an Annual Quote

Kinaxo Lands New Investors, Funding for Biomarker Development

NEW YORK (GenomeWeb News) – Germany's Kinaxo Biotechnologies said today that it has brought on two new investors and closed a financing round worth an undisclosed amount.

Kinaxo, based in Martinsried, said it will use the funding to develop novel biomarkers that allow stratification of cancer patients receiving targeted therapies.

Although he declined to disclose the amount of the financing round, Kinaxo CEO Andreas Jenne told GWDN that the company plans to invest €3 million to €4 million ($4.5 million to $5.9 million) in biomarker development over the next two years.

Jenne also said that Kinaxo plans to expand its PhosphoScout phosphoproteomics services, which uses mass spectrometry to investigate phosphorylation events in cellular signal transduction pathways and their response to drug treatment.

New investors Leifina and Conmit Invest joined existing institutional investors Mountain Partners, BioM, High-Tech Gründerfonds, the Max Planck Society, and the KfW ERP Start-Fonds in the financing round, Kinaxo said.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.